Literature DB >> 34302613

Clinical factors associated with composition of lung microbiota and important taxa predicting clinical prognosis in patients with severe community-acquired pneumonia.

Sisi Du1,2,3, Xiaojing Wu1,2,3, Binbin Li1,2,3, Yimin Wang1,2,3, Lianhan Shang1,2,3,4, Xu Huang1,2,3, Yudi Xia1,2,3, Donghao Yu1,2,3,5, Naicong Lu1,2,3, Zhibo Liu1,2,3, Chunlei Wang1,2,3, Xinmeng Liu1,2,3, Zhujia Xiong1,2,3, Xiaohui Zou1,2,3, Binghuai Lu1,2,3, Yingmei Liu1,2,3, Qingyuan Zhan6,7,8, Bin Cao9,10,11,12.   

Abstract

Few studies have described the key features and prognostic roles of lung microbiota in patients with severe community-acquired pneumonia (SCAP). We prospectively enrolled consecutive SCAP patients admitted to ICU. Bronchoscopy was performed at bedside within 48 h of ICU admission, and 16S rRNA gene sequencing was applied to the collected bronchoalveolar lavage fluid. The primary outcome was clinical improvements defined as a decrease of 2 categories and above on a 7-category ordinal scale within 14 days following bronchoscopy. Sixty-seven patients were included. Multivariable permutational multivariate analysis of variance found that positive bacteria lab test results had the strongest independent association with lung microbiota (R2 = 0.033; P = 0.018), followed by acute kidney injury (AKI; R2 = 0.032; P = 0.011) and plasma MIP-1β level (R2 = 0.027; P = 0.044). Random forest identified that the families Prevotellaceae, Moraxellaceae, and Staphylococcaceae were the biomarkers related to the positive bacteria lab test results. Multivariable Cox regression showed that the increase in α-diversity and the abundance of the families Prevotellaceae and Actinomycetaceae were associated with clinical improvements. The positive bacteria lab test results, AKI, and plasma MIP-1β level were associated with patients' lung microbiota composition on ICU admission. The families Prevotellaceae and Actinomycetaceae on admission predicted clinical improvements.
© 2021. Higher Education Press.

Entities:  

Keywords:  7-category ordinal scale; Prevotellaceae; clinical improvements; lung microbiota; severe community-acquired pneumonia

Mesh:

Substances:

Year:  2021        PMID: 34302613      PMCID: PMC8302972          DOI: 10.1007/s11684-021-0856-3

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   9.927


Materials and methods
  43 in total

Review 1.  The Microbiome and the Respiratory Tract.

Authors:  Robert P Dickson; John R Erb-Downward; Fernando J Martinez; Gary B Huffnagle
Journal:  Annu Rev Physiol       Date:  2015-11-02       Impact factor: 19.318

Review 2.  The microbiome and critical illness.

Authors:  Robert P Dickson
Journal:  Lancet Respir Med       Date:  2015-12-12       Impact factor: 30.700

3.  Mortality among severe community-acquired pneumonia patients depends on combinations of 2007 IDSA/ATS minor criteria.

Authors:  Hai-yan Li; Qi Guo; Wei-dong Song; Yi-ping Zhou; Ming Li; Xiao-ke Chen; Hui Liu; Hong-lin Peng; Hai-qiong Yu; Xia Chen; Nian Liu; Zhong-dong Lü; Li-hua Liang; Qing-zhou Zhao; Mei Jiang
Journal:  Int J Infect Dis       Date:  2015-08-06       Impact factor: 3.623

4.  Factors associated with mortality in severe community-acquired pneumonia: A multicenter cohort study.

Authors:  Rodolfo Espinoza; José Roberto Lapa E Silva; Anke Bergmann; Ulisses de Oliveira Melo; Flávio Elias Calil; Robson Correa Santos; Jorge I F Salluh
Journal:  J Crit Care       Date:  2018-11-22       Impact factor: 3.425

5.  Topographical continuity of bacterial populations in the healthy human respiratory tract.

Authors:  Emily S Charlson; Kyle Bittinger; Andrew R Haas; Ayannah S Fitzgerald; Ian Frank; Anjana Yadav; Frederic D Bushman; Ronald G Collman
Journal:  Am J Respir Crit Care Med       Date:  2011-06-16       Impact factor: 21.405

6.  The dynamics of the pulmonary microbiome during mechanical ventilation in the intensive care unit and the association with occurrence of pneumonia.

Authors:  Tetyana Zakharkina; Ignacio Martin-Loeches; Sébastien Matamoros; Pedro Povoa; Antoni Torres; Janine B Kastelijn; Jorrit J Hofstra; B de Wever; Menno de Jong; Marcus J Schultz; Peter J Sterk; Antonio Artigas; Lieuwe D J Bos
Journal:  Thorax       Date:  2017-01-18       Impact factor: 9.139

7.  Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis.

Authors:  Robert P Dickson; John R Erb-Downward; Gary B Huffnagle
Journal:  Lancet Respir Med       Date:  2014-03       Impact factor: 30.700

Review 8.  The management of severe community acquired pneumonia in the intensive care unit.

Authors:  Adamantia Liapikou; Edmundo Rosales-Mayor; Antoni Torres
Journal:  Expert Rev Respir Med       Date:  2014-06       Impact factor: 3.772

Review 9.  Severe community-acquired pneumonia: timely management measures in the first 24 hours.

Authors:  Jason Phua; Nathan C Dean; Qi Guo; Win Sen Kuan; Hui Fang Lim; Tow Keang Lim
Journal:  Crit Care       Date:  2016-08-28       Impact factor: 9.097

Review 10.  Challenges in severe community-acquired pneumonia: a point-of-view review.

Authors:  Antoni Torres; James D Chalmers; Charles S Dela Cruz; Cristina Dominedò; Marin Kollef; Ignacio Martin-Loeches; Michael Niederman; Richard G Wunderink
Journal:  Intensive Care Med       Date:  2019-01-31       Impact factor: 17.440

View more
  2 in total

1.  Prevalence and Clinical Significance of Occult Pulmonary Infection in Elderly Patients with Type 2 Diabetes Mellitus.

Authors:  Jian Hua; Ping Huang; Honghui Liao; Xiaobing Lai; Xiaoyi Zheng
Journal:  Biomed Res Int       Date:  2021-12-02       Impact factor: 3.411

2.  Clinical Efficacy Protocol of Yinhuapinggan Granules: A Randomized, Double-Blind, Parallel, and Controlled Clinical Trial Program for the Intervention of Community-Acquired Drug-Resistant Bacterial Pneumonia as a Complementary Therapy.

Authors:  Jiaoli Wang; Haoran Hu; Haixia Du; Man Luo; Yilan Cao; Jiaping Xu; Tianhang Chen; Yilei Guo; Qixiang Li; Wen Chen; Yifei Zhang; Jin Han; Haitong Wan
Journal:  Front Pharmacol       Date:  2022-06-30       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.